Sorafenib 200 mg (Nexavar)
Sorafenib 200 mg is a generic name of Sorafenat from the Indian company Natco Pharma. It is a low molecular weight multi-kinase inhibitor. Provides a reduction in the proliferation of tumor cells in vitro. It has been shown that it suppresses both intracellular kinases (serine/threonine kinases c-CRAF, BRAF, and mutant BRAF) and receptor tyrosine kinases located on the cell surface. According to recent data, some of these kinases play a key role in the processes of angiogenesis and apoptosis.
Instructions for use:
Indications for use “Sorafenib” tablet: metastatic renal cell carcinoma; hepatocellular carcinoma; locally advanced or metastatic differentiated thyroid cancer resistant to radioactive iodine.
The recommended daily dose of Sorafenib 200 mg tablet. Take it in two meals (2 times 2 tablets) – either in between meals or with it (the fat content in food can be low or moderate, but not high); pills swallow them down with a glass of water.
After taking the pills, the maximum plasma concentration of Sorafenib tablets are reached after about 3 hours; It is allowed to take the drug both on an empty stomach, and together with food characterized by moderate fat content (if the fat content in food is high, the bioavailability of Sorafenib 200 mg decreases by about 30%). Equilibrium plasma concentrations of sorafenib tablets are reached 7 days after the start of the drug. Communication with proteins – 99.5%.
How it works:
In patients with cancer, a change in DNA (genetic material) causes a signal that causes the appearance of abnormal cancer cells. “Sorafenate 200 mg” block this signal, and thus stop the production of these cancer cells.
Pregnancy, lactation (breastfeeding), child age, hypersensitivity to sorafenib 200 mg.
The recommended daily dose of sorafenib tablet is 800 mg in 2 doses either between meals or with a diet containing low or moderate amounts of fat.
- Treatment is continued for as long as clinical efficacy is maintained or until an unacceptable toxic effect appears.
- The development of adverse reactions may require the temporary cessation and/or reduction of the dose of sorafenib. If necessary, the dose of sorafenib tablet can be reduced to 400 mg 1 time/day.
- With the development of skin toxicity, a dose reduction of sorafenib is required.
There were no clinical pharmacological reactions with CYP3A4 inhibitors and warfarin, while cytochrome inducers CYP3A4 reduce the therapeutic effect of Sorafenib and its plasma concentration. Possible increase in cyclophosphamide levels.
Sorafenib tablets Brand Name in India
- Sorafenat (Manufactured by Natco)
- Soranib (Manufactured by Cipla)
From the skin: very often – skin rash, palmar and plantar erythrodysesthesia, erythema, pruritus, alopecia; often – dry skin, peeling skin, acne, exfoliative dermatitis; infrequently – eczema, erythema multiforme, folliculitis;